A Phase 2 interventional study of Ranolazine and Ranolazine in Persistent Atrial Fibrillation, sponsored by Menarini Group. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.
Sponsored by Menarini Group · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.
Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 128th largest by enrollment of the 284 interventional ones that give a count, is one of 19 that started in 2012, is one of 21 in phase 2, and was the 105th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 960 are open to participants now.
Browse Atrial Fibrillation studies →60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:
Technical University of Munich · Sites in Germany
Ages 18–99
St. Josefs-Hospital Wiesbaden GmbH · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Bayer · Sites in Germany, United States, Belgium and 5 more countries
Ages 18–85
Asklepios proresearch · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
417 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 44 · Phase 4 51
First in 2000; this study’s year is marked. 19 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.
Median enrollment 200 across the 284 interventional studies, 515 across the 131 observational. Of the 289 that completed or were terminated, 92 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
214 of 417 have an industry lead sponsor. The 10 most frequent:
Menarini Group is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Menarini Group has 1 study filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
29 of the studies in Atrial Fibrillation with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT05294445Asklepios proresearchFrom the Emergency Department Directly to Ablation of Atrial Fibrillation Study | 2026-11-16 |
| NCT05005949Medtronic Cardiac Ablation SolutionsSTOP Persistent AF PAS | 2026-12 |
| NCT05557526Evangelical Hospital DüsseldorfOptimizing Quality of Life by Improved Patient Expectation Following Atrial Fibrillation Catheter Ablation | 2026-12 |
| NCT07429214Biosense Webster, Inc.A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF | 2026-12-30 |
Add all 29 to your calendar (.ics) → With an account.
Among the 417 studies in Atrial Fibrillation with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low, intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful electrical cardioversion in patients with persistent atrial fibrillation (AFib).
After successful cardioversion and subsequent randomisation, patients report trans-telephonic EGCs on a daily basis to a central core ECG facility.
Maximum treatment duration is 112 days (16 weeks).
Patients with persistent AFib are screened for eligibility and undergo direct current cardioversion (DCC). If DCC is successful (defined as persistence of sinus rhythm 2 h post-DCC) patients meeting all the inclusion criteria and none of the exclusion criteria are randomly assigned to the treatment arms (Ranolazine low, intermediate, high dose or placebo, given BID).
Transtelephonic ECG devices (TT-ECG) are used for recording of AFib recurrence to be read by a Central ECG Core Laboratory. Any symptoms indicative of AFib have to be recorded by the patient in a diary.
Study Visits are held for screening (Visit 1), at DCC and randomisation (Visit 2), one week post DCC (Visit 3), after 8 weeks of treatment (Visit 4), and at end of treatment (Visit 5). A safety follow-up telephone call is held 2 weeks after end of treatment.
12-Lead ECGs are performed at every visit.
Safety evaluations include regular safety laboratory blood and urine tests, 12-lead ECGs and the continuous recording of adverse events.
A double-dummy technique is used to ensure double-blind conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ranolazine, low dose, oral, BID
Drug: Ranolazine
Ranolazine, intermediate dose, oral, BID
Drug: Ranolazine
Ranolazine, high dose, oral, BID
Drug: Ranolazine
Placebo (sugar pill), oral, BID.
Drug: Placebo
Oral administration, BID; for a maximum of 112 days.
Also known as: Ranexa (R)
Oral administration, BID; for a maximum of 112 days.
Also known as: Ranexa (R)
Oral administration, BID; for a maximum of 112 days.
Also known as: Ranexa (R)
Oral administration, BID; for a maximum of 112 days.
Also known as: Sugar pill
Time From Randomization to First Documented AF Recurrence.
Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first. Patients discontinuing the study without AF were censored at the time of the last available ECG.
Time frame: 16 weeks (112 days)
Number of Patients With Documented AF Recurrences
Time frame: 16 weeks (112 days)
Time From Randomization to First Documented and Confirmed AF Recurrence
A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation.
Time frame: 16 weeks (112 days)
Number of Patients With Documented and Confirmed AF Recurrences
Time frame: 16 weeks (112 days)
Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion
Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state.
Time frame: 16 weeks (112 days)
Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence
Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion)
Time frame: 16 weeks (112 days)
| Milestone | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Started | 67 | 60 | 58 | 56 |
| Completed | 30 | 34 | 34 | 24 |
| Not completed | 37 | 26 | 24 | 32 |
| Withdrew: Randomized but did not start treatment | 2 | 0 | 0 | 1 |
| Withdrew: Discontinued at af recurrence | 35 | 26 | 24 | 31 |
Time to first AF recurrence reported by patient-reported TT-ECG or 12-Lead ECG at the study site, whichever occurred first. Patients discontinuing the study without AF were censored at the time of the last available ECG.
| Days | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Time From Randomization to First Documented AF Recurrence. | 51.0 (9.0 to NA) | NA (68.0 to NA) | 117.0 (17.0 to NA) | 58.0 (16.0 to NA) |
| participants | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Number of Patients With Documented AF Recurrences | 37 | 25 | 23 | 31 |
A confirmed AF recurrence was defined as a documented AF recurrence which was confirmed by a consecutive ECG performed at least 1 hour after first AF documentation.
| Days | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Time From Randomization to First Documented and Confirmed AF Recurrence | 73.0 (11.0 to NA) | NA (NA to NA) | NA (117.0 to NA) | NA (38.0 to NA) |
| participants | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Number of Patients With Documented and Confirmed AF Recurrences | 31 | 19 | 16 | 24 |
Excluding patients with early relapses (within 48 hours) while the study drug, started after cardioversion, had not yet reached steady-state.
| Days | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Time From Randomization to First Documented AF Recurrence in Patients With Sinus Rhythm 48 Hours After Cardioversion | 56.0 (11.0 to NA) | NA (98.0 to NA) | 117.0 (18.0 to NA) | 78.0 (37.0 to NA) |
Documented AF recurrences in those patients who did not experience early relapses (within 48 hours after cardioversion)
| participants | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Number of Patients in Sinus Rhythm 48 Hours After Cardioversion With Documented AF Recurrence | 32 | 19 | 21 | 27 |
Collected over 16 weeks (112 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranolazine Low Dose | — | 2/65 (3.1%) | 51/65 (78.5%) |
| Ranolazine Intermediate Dose | — | 3/60 (5%) | 46/60 (76.7%) |
| Ranolazin High Dose | — | 3/58 (5.2%) | 42/58 (72.4%) |
| Placebo | — | 4/55 (7.3%) | 41/55 (74.5%) |
| Event | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Angina PectorisCardiac disorders | 0/65 | 1/60 | 0/58 | 1/55 |
| Atrial FibrillationCardiac disorders | 0/65 | 0/60 | 0/58 | 1/55 |
| Sick Sinus SyndromeCardiac disorders | 0/65 | 0/60 | 0/58 | 1/55 |
| Ventricular TachycardiaCardiac disorders | 0/65 | 0/60 | 0/58 | 1/55 |
| Sudden DeathGeneral disorders | 0/65 | 0/60 | 0/58 | 1/55 |
| HypertensionVascular disorders | 1/65 | 0/60 | 0/58 | 1/55 |
| Atrial FlutterCardiac disorders | 0/65 | 0/60 | 1/58 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 0/65 | 0/60 | 1/58 | 0/55 |
| SyncopeNervous system disorders | 0/65 | 0/60 | 1/58 | 0/55 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/65 | 0/60 | 1/58 | 0/55 |
| Event | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo |
|---|---|---|---|---|
| Atrial FibrillationCardiac disorders | 29/65 | 24/60 | 23/58 | 27/55 |
| DizzinessNervous system disorders | 6/65 | 2/60 | 14/58 | 7/55 |
| PalpitationsCardiac disorders | 9/65 | 11/60 | 11/58 | 6/55 |
| FatigueGeneral disorders | 11/65 | 10/60 | 9/58 | 5/55 |
| Chest PainGeneral disorders | 8/65 | 7/60 | 4/58 | 6/55 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/65 | 7/60 | 5/58 | 6/55 |
| AstheniaGeneral disorders | 4/65 | 1/60 | 5/58 | 2/55 |
| HeadacheNervous system disorders | 2/65 | 2/60 | 5/58 | 2/55 |
| NauseaGastrointestinal disorders | 5/65 | 1/60 | 4/58 | 0/55 |
| VertigoEar and labyrinth disorders | 1/65 | 1/60 | 4/58 | 2/55 |
ITT-population (excluding 3 randomized patients who never started study drug)
| Age, Continuous(years) | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 66.9 ± 11.8 | 65.5 ± 8.5 | 63.6 ± 11.3 | 65.2 ± 9.5 | 65.3 ± 10.4 |
| Sex: Female, Male(Participants) | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 19 | 9 | 12 | 14 | 54 |
| Male | 46 | 51 | 46 | 41 | 184 |
| Time since AF diagnosis(months) | Ranolazine Low Dose | Ranolazine Intermediate Dose | Ranolazin High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 10.5 ± 24.0 | 7.2 ± 12.9 | 15.5 ± 28.2 | 6.9 ± 13.5 | 10.0 ± 20.7 |
The record gives a start of Jan 2012, a primary completion of Oct 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranolazine